Background: Powered exoskeletons are designed to safely facilitate ambulation in patients with spinal cord injury (SCI). We conducted the first meta-analysis of the available published research on the clinical effectiveness and safety of powered exoskeletons in SCI patients.
Nevro Corp has received European and Australian approval for its Senza spinal cord stimulator, designed to reduce pain, to be...
Boston Scientific Corporation has received CE Mark approval and has begun the European market launch of the Precision Spectra Spinal...
The FDA has approved the Precision Spectra Spinal Cord Stimulator (SCS) System, from Boston Scientific, for treating Chronic Pain. The...
Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of the anterior horn cells of the spinal cord, leading to muscular paralysis with muscular atrophy. No effective treatment of this disorder...
This guideline covers the assessment and early management of spinal column and spinal cord injury in pre-hospital settings (including ambulance services), emergency departments and major trauma centres.
Boston Scientific has presented new data demonstrating that the Precision Spectra Spinal Cord Stimulator (SCS) System provides 1.5 times better...
Boston Scientific Corporation has announced that the FDA has approved the Spectra WaveWriter Spinal Cord Stimulator (SCS) System.
Axonics Modulation Technologies, Inc., announced that it has received the CE mark for its Sacral Neuromodulation External Trial System to...
Boston Scientific has announced a limited market release of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) systems.